Important Dates

no event

Latest News

Announcement: GENERATION HD1 study results published

GENERATION HD1 — This Phase 3 trial was stopped in March 2021 following a benefit–risk assessment by an independent data monitoring committee. A letter published 07/12/2023 in the New England Journal of Medicine (DOI: 10.1056/NEJMc2300400) details ad hoc analyses conducted on the week 69 data. Findings suggest that younger participants with lower disease burden may […]

Read More…

EHDN Plenary Meeting and Enroll-HD Congress Strasbourg 2024 — Save the Date!

Dear Friends of EHDN,   It is our pleasure to cordially invite you to the EHDN Plenary Meeting and Enroll-HD Congress Thursday 12th to Saturday 14th September, 2024 Strasbourg, France   The EHDN and Enroll-HD 2024 is a collaborative event combining the EHDN Plenary Meeting and the Enroll-HD Congress. The event will be held across […]

Read More…

Good news from PTC and uniQure!

On 21 June 2023, positive findings from both PTC Therapeutics and uniQure were shared with the HD community on their respective huntingtin (HTT)-lowering approaches to treating HD. PTC’s interim 12-week data from the global PIVOT-HD trial of PTC518 showed dose-dependent lowering of HTT protein levels, confirmed the intended exposure in cerebrospinal fluid, and indicated a […]

Read More…